PL444608A1 - Sposób wytwarzania kopolimeru amfifilowego, jego formulacji leczniczej oraz jej zastosowanie - Google Patents

Sposób wytwarzania kopolimeru amfifilowego, jego formulacji leczniczej oraz jej zastosowanie

Info

Publication number
PL444608A1
PL444608A1 PL444608A PL44460823A PL444608A1 PL 444608 A1 PL444608 A1 PL 444608A1 PL 444608 A PL444608 A PL 444608A PL 44460823 A PL44460823 A PL 44460823A PL 444608 A1 PL444608 A1 PL 444608A1
Authority
PL
Poland
Prior art keywords
producing
formulation
amphiphilic copolymer
medicinal formulation
poly
Prior art date
Application number
PL444608A
Other languages
English (en)
Inventor
Monika Gosecka
Mateusz Gosecki
Małgorzata Urbaniak
Barbara Klajnert-Maculewicz
Anna Janaszewska
Monika Marcinkowska
Original Assignee
Centrum Badań Molekularnych i Makromolekularnych Polskiej Akademii Nauk
Uniwersytet Łódzki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centrum Badań Molekularnych i Makromolekularnych Polskiej Akademii Nauk, Uniwersytet Łódzki filed Critical Centrum Badań Molekularnych i Makromolekularnych Polskiej Akademii Nauk
Priority to PL444608A priority Critical patent/PL444608A1/pl
Publication of PL444608A1 publication Critical patent/PL444608A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2603—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen
    • C08G65/2606—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups
    • C08G65/2609—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups containing aliphatic hydroxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Zgłoszenie rozwiązuje zagadnienie sposobu wytwarzania amfifilowego kopolimeru nieliniowego z hydrofobowym rdzeniem z poli(eteru benzylowo-glicydylowego) i hydrofilową powłoką z poli(eteru glicerylowo-glicerylowego), jego formulacji z trudno rozpuszczalnym w wodzie nifuratelem oraz zastosowanie tej formulacji w terapii przeciwnowotworowej i skojarzonej terapii przeciwnowotworowej z klotrimazolem na przykładzie raka szyjki macicy.
PL444608A 2023-04-26 2023-04-26 Sposób wytwarzania kopolimeru amfifilowego, jego formulacji leczniczej oraz jej zastosowanie PL444608A1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL444608A PL444608A1 (pl) 2023-04-26 2023-04-26 Sposób wytwarzania kopolimeru amfifilowego, jego formulacji leczniczej oraz jej zastosowanie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL444608A PL444608A1 (pl) 2023-04-26 2023-04-26 Sposób wytwarzania kopolimeru amfifilowego, jego formulacji leczniczej oraz jej zastosowanie

Publications (1)

Publication Number Publication Date
PL444608A1 true PL444608A1 (pl) 2024-10-28

Family

ID=93289639

Family Applications (1)

Application Number Title Priority Date Filing Date
PL444608A PL444608A1 (pl) 2023-04-26 2023-04-26 Sposób wytwarzania kopolimeru amfifilowego, jego formulacji leczniczej oraz jej zastosowanie

Country Status (1)

Country Link
PL (1) PL444608A1 (pl)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367762B2 (en) * 2008-11-24 2013-02-05 Byk-Chemie Gmbh Compositions comprising glycidyl ether copolymers
CN108530642A (zh) * 2017-11-24 2018-09-14 四川大学 可生物降解的三嵌段杂臂星形双亲性高分子材料及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367762B2 (en) * 2008-11-24 2013-02-05 Byk-Chemie Gmbh Compositions comprising glycidyl ether copolymers
CN108530642A (zh) * 2017-11-24 2018-09-14 四川大学 可生物降解的三嵌段杂臂星形双亲性高分子材料及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
F. WURM I INNI: "Macromolecules 2008, 41, 1909-1911", „SYNTHESIS AND CHARACTERIZATION OF POLY(GLYCERYL GLYCEROL) BLOCK COPOLYMERS" *
P. ZIEMCZONEK I INNI: "International Journal of Molecular Sciences 2021, 22(16), 8386, DOI: 10.3390/ijms22168386", „STAR-SHAPED POLY(FURFURYL GLYCIDYL ETHER)-BLOCK-POLY(GLYCERYL GLYCEROL ETHER) AS AN EFFICIENT AGENT FOR THE ENHANCEMENT OF NIFURATEL SOLUBILITY AND FOR THE FORMATION OF INJECTABLE AND SELF-HEALABLE HYDROGEL PLATFORMS FOR THE GYNAECOLOGICAL THERAPIES *

Similar Documents

Publication Publication Date Title
BR112021023901A2 (pt) Conjugado anticorpo-fármaco anti-trop2, composição farmacêutica, método para tratar ou prevenir câncer, e, uso de um conjugado anticorpo-fármaco anti-trop2 na fabricação de um fármaco para o tratamento ou prevenção do câncer
Huanbutta et al. Design and development of zero-order drug release gastroretentive floating tablets fabricated by 3D printing technology
Gavin et al. Layered nanoemulsions as mucoadhesive buccal systems for controlled delivery of oral cancer therapeutics
CL2008002406A1 (es) Composicion de pelicula de disolucion oral que comprende un agente activo cosmetico o farmaceutico, y un copolimero de injerto de poli(alcohol de vinilo)-polietilenglicol (divisional de la solicitud 1825-04).
KR880008800A (ko) 난용성 활성성분을 위한 치료계
BRPI0821616B8 (pt) composição micelar de copolímero de bloco anfifílico contendo taxano e método para preparação da mesma
CY1105626T1 (el) Σκευασματα τυπου φυραματος που περιλαμβανουν διοξειδιο πυριτιου
SV2006002256A (es) Uso de un anticuerpo para tratar la vasculitis
MX2019003134A (es) Terapia de combinacion.
WO2019004669A3 (ko) 광감작제를 포함한 마이크로버블-나노입자 복합체 및 이를 포함하는 항암 치료제
Zabetian et al. A case of idiopathic granulomatous mastitis associated with erythema nodosum, arthritis, and reactive cough
EA201891575A1 (ru) Составы для лечения рака мочевого пузыря
WO2020222139A9 (en) Formulations and methods for drug instillation into the bladder and treatment of bladder ailments
PL444608A1 (pl) Sposób wytwarzania kopolimeru amfifilowego, jego formulacji leczniczej oraz jej zastosowanie
BR112021017878A2 (pt) Carbonato de magnésio com superfície reagida, sistema de liberação, formulação de cuidados domiciliares, métodos para preparar um carbonato de magnésio com superfície reagida e para preparar um sistema de liberação, e, uso de um carbonato de magnésio com superfície reagida e de um sistema de liberação
MX2022011790A (es) Dispositivos, metodos de ingenieria de tejidos y medicina regenerativa y celular in vivo empleando andamios hechos de material absorbible.
ES2526095T3 (es) Vesículas que comprenden un copolímero en bloque anfifílicos para uso en administración epitelial
MY194787A (en) External agent for skin or mucous membrane and production method thereof, and base for external agent for skin or mucous membrane
BR112022008655A2 (pt) Composições de copolímero em bloco responsivas ao ph, micelas, e métodos de uso
Çalışkan et al. A case of microcystic lymphatic malformation successfully treated with topical sirolimus
PH12021551805A1 (en) Treatment of skin lesions and pruritus in prurigo nodularis patients
MX2020011581A (es) Catéter de globo.
PL445173A1 (pl) Sposób wytwarzania formulacji leczniczej klotrimazolu z amfifilowym kopolimerem i jej zastosowanie w terapii przeciwnowotworowej i skojarzonej terapii przeciwnowotworowej z nifuratelem
MX383682B (es) Tratamiento para cancer de mama usando una combinación de una formulación liposomal catiónica de taxano, una formulación no liposomal de taxano y un agente activo adicional.
CL2019001262A1 (es) Métodos para tratar las carcinomas uroteliales del tracto superior.